XJPX4880
Market cap102mUSD
Jan 14, Last price
814.00JPY
1D
-1.93%
1Q
-31.94%
IPO
4.36%
Name
CellSource Co Ltd
Chart & Performance
Profile
CellSource Co., Ltd. engages in the regenerative medicine-related and consumer businesses. It also offers Signalift, an anti-aging product. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|
2023‑10 | 2022‑10 | 2021‑10 | 2020‑10 | 2019‑10 | 2018‑10 | 2017‑10 | |
Income | |||||||
Revenues | 4,510,544 5.54% | 4,273,829 46.25% | |||||
Cost of revenue | 1,956,203 | 1,722,571 | |||||
Unusual Expense (Income) | |||||||
NOPBT | 2,554,341 | 2,551,258 | |||||
NOPBT Margin | 56.63% | 59.69% | |||||
Operating Taxes | 316,540 | 565,796 | |||||
Tax Rate | 12.39% | 22.18% | |||||
NOPAT | 2,237,801 | 1,985,462 | |||||
Net income | 923,142 -9.30% | 1,017,842 56.26% | |||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 1,461,669 | 15,266 | |||||
BB yield | |||||||
Debt | |||||||
Debt current | 20,251 | ||||||
Long-term debt | 174,833 | ||||||
Deferred revenue | |||||||
Other long-term liabilities | 148,709 | (1,569) | |||||
Net debt | (4,737,978) | (3,295,009) | |||||
Cash flow | |||||||
Cash from operating activities | 846,691 | 847,603 | |||||
CAPEX | (349,000) | (99,167) | |||||
Cash from investing activities | (624,080) | (169,388) | |||||
Cash from financing activities | 1,449,123 | 14,421 | |||||
FCF | 1,153,008 | 1,771,748 | |||||
Balance | |||||||
Cash | 4,781,022 | 3,123,580 | |||||
Long term investments | 152,040 | 171,429 | |||||
Excess cash | 4,707,535 | 3,081,318 | |||||
Stockholders' equity | 4,802,716 | 3,787,225 | |||||
Invested Capital | 1,740,296 | 180,566 | |||||
ROIC | 233.00% | 4,017.44% | |||||
ROCE | 39.62% | 78.18% | |||||
EV | |||||||
Common stock shares outstanding | 19,260 | 19,213 | |||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | 2,620,717 | 2,596,680 | |||||
EV/EBITDA | |||||||
Interest | 379 | 11 | |||||
Interest/NOPBT | 0.01% | 0.00% |